NCT05120596View on ClinicalTrials.gov

First in Human Study of T3P-Y058-739 (T3P)

PHASE1/PHASE2RecruitingINTERVENTIONAL
Enrollment

100

Participants

Timeline

Start Date

April 26, 2022

Primary Completion Date

February 28, 2027

Study Completion Date

October 15, 2027

Conditions
Advanced Solid Tumor
Interventions
DRUG

Pembrolizumab+T3P-Y058-739

intravenous infusion or intratumoural injection

DRUG

T3P-Y058-739 (IV)

Intravenous infusion

DRUG

T3P-Y058-739 (IT)

Intratumoral use

Trial Locations (11)

1011

RECRUITING

Centre Hospitalier Universitaire Vaudois Lausanne (CHUV), Lausanne

3010

RECRUITING

University Hospital Bern (Inselspital), Bern

8091

RECRUITING

University Hospital of Zürich (Universitätsspital Zürich), Zurich

28041

RECRUITING

Hospital Universitario 12 De Octubre, Madrid

28046

RECRUITING

Hospital Universitario La Paz, Madrid

08035

RECRUITING

Vall d'Hebron Institute of Oncology, Barcelona

08908

RECRUITING

Institut Catala D'oncologia, L'Hospitalet de Llobregat

G12 0YN

RECRUITING

Cancer Research UK Clinical trials; Unit Partner in CaCTUS- Cancer clinical trials Unit Scotland; Beatson West of Scotland Cancer Centre, Glasgow

LS9 7TF

RECRUITING

Leeds Clinical Research Facility, Leeds

SW3 6JJ

RECRUITING

Royal Marsden NHS Foundation Trust, London

SO16 6YD

RECRUITING

University Hospital Southampton NHS Foundation Trust, Southampton

All Listed Sponsors
lead

T3 Pharmaceuticals AG

INDUSTRY